General information and education, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Always consult a SEBI-registered adviser.
1. At a Glance
A company with ₹43.79 crore of quarterly revenue has agreed to spend roughly ₹3,000 crore buying things. That is the June 2026 quarter for Gujarat Themis Biosyn Limited, a Vapi-based fermentation house whose entire annual topline of ₹165.82 crore in FY26 would cover about a twentieth of its own shopping list.
The quarter itself was almost restful by comparison. Revenue rose 22.1% year-on-year to ₹43.79 crore. Operating profit reached ₹20.80 crore against ₹13.92 crore. PAT came in at ₹11.07 crore, up 22.1%. EPS was ₹1.02 versus ₹0.83.
Around that tidy little P&L, the corporate calendar looked like someone had spilled a filing cabinet. In April, an agreement to acquire 13 anti-TB and anti-infective brands from Sanofi for about €158 million. In May, an agreement to buy 100% of MicroBiopharm Japan for JPY 21.5 billion. In June, arbitration initiated against Optimus Drugs claiming ₹75 crore of break fees, ₹23.8 lakh of interest and ₹15 crore of damages. In July, CARE placed the bank facilities on Rating Watch with Negative Implications, and an indirect encumbrance was disclosed over 5.12 crore shares. Shareholders approved a ₹1,000 crore QIP on 10 July.
Balance-sheet-wise, total assets went from ₹301.31 crore to ₹503.43 crore in one year, and borrowings from ₹30.47 crore to ₹161.82 crore. Two subsidiaries were incorporated during the quarter — one in Japan, one in Ireland — with revenue of nil, profit of nil, and no capital remitted, which is the corporate equivalent of buying the envelope before writing the letter.
Now the fermenters.
2. Introduction
Gujarat Themis Biosyn was incorporated in 1981, originally as a joint-sector company with GIIC Ltd and Chemosyn (P) Ltd. Its founding claim to fame is a good one: via a technical and financial collaboration with Yuhan Corporation of South Korea, it became India’s first company to start commercial production of the anti-tuberculosis drug Rifampicin. Forty-five years later it is still in Vapi, still fermenting, and now approximately 200 employees at the plant site are engaged in the same broad activity as the founders — persuading bacteria to make medicine on a deadline.
The company is actively managed by Themis Medicare Ltd, itself a JV company of Gedeon Richter Ltd of Hungary, and has been since 2007 per CARE. Total employee count went from 101 in FY19 to 235 in FY26 — a headcount that took seven years to double while the balance sheet managed it in twelve months.
The recent chapters arrived in a hurry. FY26 saw revenue of ₹165.82 crore against ₹150.80 crore, PAT of ₹46.68 crore against ₹48.77 crore, and depreciation jump from ₹5.37 crore to ₹12.92 crore as the new plants switched on. Capacity was raised from 216 MT to 432 MT of fermentation, at a project cost of ₹135 crore, completed in December 2025 with trial production in Q4FY26. An 18 MW hybrid captive power project — 9 MW solar, 9 MW wind — has consumed ₹100 crore of a ₹110 crore budget, with management expecting commissioning from August 2026.
Then, in the space of thirty days across April and May 2026, a company doing ₹166 crore of revenue signed up for a Japanese CDMO and a European brand portfolio. CARE’s July note sizes the combined transactions at roughly ten times GTBL’s tangible net worth. Management, on the August call, described the funding as “pretty much” secured, pending some last-minute approvals — a phrase that carries a lot of weight for its length.
Shareholders approved a ₹1,000 crore QIP on 10 July 2026. A second postal ballot filed 23 July seeks approval for the ₹1,000 crore QIP and ₹1,500 crore of debt issuance, with voting closing 22 August 2026.
US
Now live
US Stocks terminal is live
13,000+ US tickers · EDGAR fundamentals · screener and filings feed — the same terminal, for American markets.
Explore →
3. Business Model: WTF Do They Even Do?
They grow antibiotics. Not metaphorically — in tanks, with aerobic bacteria, at a facility in Vapi that the company describes as an environment-friendly and sustainable process, which is a generous way of saying the workforce includes several trillion microorganisms on no fixed salary.
The product list is two items long. Rifamycin S is an intermediate for Rifampicin, an antibiotic used against several bacterial infections including tuberculosis, Mycobacterium avium complex, leprosy and Legionnaires’ disease. Rifamycin O is an intermediate for Rifaximin, used for traveller’s diarrhoea, irritable bowel syndrome and hepatic encephalopathy. That is the whole catalogue. Most listed manufacturers need a product brochure; GTBL needs an index card.
Being an intermediates maker means GTBL sells to the people who make the drug, not the people who take it. Sales volume of Rifamycin S and O was 224,723 kg in FY26 against 198,313 kg, at a realisation of ₹7,556 per kg against ₹7,469. Installed capacity for the two products stood at 432,000 kg per year in FY26, doubled from 216,000. The presentation puts current portfolio capacities at up to 990 KL.
The customer list has historically been as short as the product list. Until FY25 the company catered to two major customers — Lupin at 56% of sales and Optimus Drugs at the balance 44% in FY24 — both on ‘take or pay’ terms. Disclosed customer share for Lupin ran 45%, 44%, 61% and 53% across the last four disclosed years, with Optrix Laboratories at 55%, 56%, 37% and 43%. Per CARE, ODPL contributed around 44% of revenue till H1FY26, after which, in light of significant organisational changes at ODPL, its contribution declined substantially; GTBL onboarded new customers in H2FY26. Management’s stated ambition on the August call is to sell intermediate to anyone in the country and outside who manufactures these APIs, which is one way to solve a two-customer problem.
The forward move is into APIs themselves — Rifampicin, Rifapentine and Rifaximin — with the new unit commercially started and, per CARE, product approvals expected in H2FY27. Management explained the API ramp had been stuck for a simple reason: with capacity sold out, there was no spare intermediate to convert. Fermentation, as management put it, runs at 0 or 100. A
